Two decisive milestones propel Bioscibex forward—the Monthey-based biotech startup hosted at BioArk and backed by the Ark Foundation. The company launches its Innosuisse project with HES-SO Valais-Wallis and HSLU partners while securing Kick Fund investment—clear validation of SWINGO’s scientific excellence and commercial promise.
Bioscibex advances its mission to automate mammalian cell culture for biopharma with the newly approved Innosuisse project: “Novel automated single-use bioreactor for one-step seed train production: from cell revival to N-stage inoculation in one system.”
This nine-month effort refines SWINGO, the single-use bioreactor-incubator scaling cultures from 30 mL to 30 L without manual passaging—from vial thaw to pilot scale.
Seed train bottleneck meets SWINGO solution
Monoclonal antibodies and biologics save lives, yet production starts with slow, manual, error-prone mammalian cell expansion. The project reimagines seed trains as one-step automated workflows—speeding early growth, boosting robustness, cutting costs, and hastening patient access to therapies.
HES-SO Valais-Wallis and HSLU drive optimization
A powerhouse academic duo powers this advance. At HES-SO Valais-Wallis, Prof. Valentin Jossen leads process intensification, automation and lab validation of enhanced SWINGO in Valais facilities. Hochschule Luzern (HSLU)’s Prof. Dr. Ulf Christian Müller delivers 3D modeling and simulation (CFD) for superior bioreactor control and performance.
Kick Fund powers SWINGO’s Salzburg 2026 debut
Kick Fund-championing Switzerland’s top post-Venture Kick startups – provides essential funding and strategic guidance, perfectly timed as Bioscibex prepares SWINGO’s commercial launch at the 29th ESACT Meeting in Salzburg, June 2026 – a premier global forum for cell culture and bioprocessing experts.
Kick Fund’s support fast-tracks quality systems, industrialization, and biopharma go-to-market strategies ahead of the launch in Austria.
By condensing traditional seven-step cell culture into just two automated stages, SWINGO emerges as a next-generation biotool for agile, efficient biologics manufacturing.
